Unraveling the mechanism of the farnesyltransferase enzyme

Farnesyltransferase enzyme (FTase) is currently one of the most fascinating targets in cancer research. Studies in other areas, namely in the fight against parasites and viruses, have also led to very promising results. However, in spite of the thrilling achievements in the development of farnesyltransferase inhibitors (FTIs) over the past few years, the farnesylation mechanism remains, to some degree, a mystery. This review tries to shed some light on this puzzling enzyme by analyzing seven key mechanistic dilemmas, based on recent studies that have dramatically changed the way this enzyme is currently perceived.

[1]  C. Marshall,et al.  All ras proteins are polyisoprenylated but only some are palmitoylated , 1989, Cell.

[2]  Zhanghua Wu,et al.  Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. , 1998, Biochemistry.

[3]  J. Mazières,et al.  Perspectives on farnesyl transferase inhibitors in cancer therapy. , 2004, Cancer letters.

[4]  Stephen B. Long,et al.  Reaction path of protein farnesyltransferase at atomic resolution , 2002, Nature.

[5]  Channing J Der,et al.  Farnesyltransferase inhibitors: promises and realities. , 2002, Current opinion in pharmacology.

[6]  S. Croft,et al.  Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. , 2004, Journal of medicinal chemistry.

[7]  S. Moores,et al.  Sequence dependence of protein isoprenylation. , 1991, The Journal of biological chemistry.

[8]  P. Casey,et al.  The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures. , 2000, Structure.

[9]  C. Der,et al.  Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Brown,et al.  Cloning and expression of a cDNA encoding the alpha subunit of rat p21ras protein farnesyltransferase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Casey,et al.  Substrate Binding Is Required for Release of Product from Mammalian Protein Farnesyltransferase* , 1997, The Journal of Biological Chemistry.

[12]  Zhengliang L. Wu,et al.  Farnesyl protein transferase: Identification of K164α and Y300β as catalytic residues by mutagenesis and kinetic studies , 1999 .

[13]  Ping Liu,et al.  In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. , 2003, The Journal of clinical investigation.

[14]  C. Poulter,et al.  Yeast protein farnesyltransferase: a pre-steady-state kinetic analysis. , 1997, Biochemistry.

[15]  D. Chakrabarti,et al.  Protein Farnesyltransferase and Protein Prenylation inPlasmodium falciparum * , 2002, The Journal of Biological Chemistry.

[16]  S. Clarke,et al.  Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. , 1992, Annual review of biochemistry.

[17]  R. Donehower,et al.  Evolving therapies: Farnesyltransferase inhibitors , 2002, Current oncology reports.

[18]  P. Casey,et al.  Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.

[19]  C. Poulter,et al.  Yeast protein farnesyltransferase. pKas of peptide substrates bound as zinc thiolates. , 1999, Biochemistry.

[20]  P. Casey,et al.  Biochemistry of protein prenylation. , 1992, Journal of lipid research.

[21]  C. Fierke,et al.  Function and mechanism of zinc metalloenzymes. , 2000, The Journal of nutrition.

[22]  S. Sebti,et al.  Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. , 1997, Pharmacology & therapeutics.

[23]  S. Sebti.  Blocked pathways: FTIs shut down oncogene signals. , 2003, The oncologist.

[24]  N. Rosen,et al.  A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. , 1995, Cancer research.

[25]  P. Casey,et al.  Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release. , 1995, Biochemistry.

[26]  B. Giros,et al.  cDNA cloning and expression of rat and human protein geranylgeranyltransferase type-I. , 1994, The Journal of biological chemistry.

[27]  R. Gibbs,et al.  ON THE STEREOCHEMICAL COURSE OF HUMAN PROTEIN-FARNESYL TRANSFERASE , 1996 .

[28]  S. Rodenhuis.  ras and human tumors. , 1992, Seminars in cancer biology.

[29]  D. Cruickshank,et al.  Remarks about protein structure precision. , 1999, Acta crystallographica. Section D, Biological crystallography.

[30]  A. Kral,et al.  Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice , 1995, Nature Medicine.

[31]  G. Klebe,et al.  Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo. , 2004, Angewandte Chemie.

[32]  C. Poulter,et al.  A mechanism for posttranslational modifications of proteins by yeast protein farnesyltransferase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  L. Beese,et al.  Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes. , 2004, Biochemistry.

[34]  J. Karp,et al.  Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. , 2003, Blood.

[35]  H. Hellinga,et al.  The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. Casey,et al.  Evidence for a Catalytic Role of Zinc in Protein Farnesyltransferase , 1997, The Journal of Biological Chemistry.

[37]  Chia‐Yu Huang,et al.  Farnesyltransferase inhibitors: recent advances , 2004 .

[38]  B. Vogelstein,et al.  Prevalence of ras gene mutations in human colorectal cancers , 1987, Nature.

[39]  D. Troyer,et al.  A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis , 1998, Molecular and Cellular Biology.

[40]  S. Rodenhuis,et al.  Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. , 1988, Cancer research.

[41]  P. Olliaro,et al.  Antimalarial compounds: from bench to bedside , 2003, Journal of Experimental Biology.

[42]  N. Kohl,et al.  Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Fierke,et al.  Role of metals in the reaction catalyzed by protein farnesyltransferase. , 2000, Biochemistry.

[44]  C. Fierke,et al.  Lysine β311 of Protein Geranylgeranyltransferase Type I Partially Replaces Magnesium* , 2004, Journal of Biological Chemistry.

[45]  K. Kaibuchi,et al.  Small GTP-binding proteins. , 1992, International review of cytology.

[46]  Crowther,et al.  Protein farnesyltransferase: structure and implications for substrate binding , 1998, Biochemistry.

[47]  B. Vallee,et al.  Active-site zinc ligands and activated H2O of zinc enzymes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Y. Reiss,et al.  Divalent cation and prenyl pyrophosphate specificities of the protein farnesyltransferase from rat brain, a zinc metalloenzyme. , 1992, The Journal of biological chemistry.

[49]  C. Poulter,et al.  Yeast protein farnesyltransferase. Site-directed mutagenesis of conserved residues in the beta-subunit. , 1997, Biochemistry.

[50]  S. Armstrong,et al.  Nonidentical subunits of p21H-ras farnesyltransferase. Peptide binding and farnesyl pyrophosphate carrier functions. , 1991, The Journal of biological chemistry.

[51]  R. M. Izatt,et al.  Thermodynamics of Proton Dissociation in Aqueous Solution. III. L-Cysteine, S-Methyl-L-cysteine, and Mercaptoacetic Acid. Determination of Cysteine Microconstants from Calorimetric Data , 1964 .

[52]  Maria João Ramos,et al.  Farnesyltransferase--new insights into the zinc-coordination sphere paradigm: evidence for a carboxylate-shift mechanism. , 2005, Biophysical journal.

[53]  D. Russell,et al.  cDNA cloning and expression of the peptide-binding β subunit of rat p21rasfarnesyltransferase, the counterpart of yeast DPR1/RAM1 , 1991, Cell.

[54]  P. Casey,et al.  Influence of metal ions on substrate binding and catalytic activity of mammalian protein geranylgeranyltransferase type-I. , 1996, The Biochemical journal.

[55]  C. Der,et al.  Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[56]  L. Beese,et al.  Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. , 2004, Biochemistry.

[57]  W. Schafer,et al.  Protein prenylation: genes, enzymes, targets, and functions. , 1992, Annual review of genetics.

[58]  C. Farnsworth,et al.  Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. , 1994, Annual review of cell biology.

[59]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[60]  C. Fierke,et al.  Mechanistic studies of rat protein farnesyltransferase indicate an associative transition state. , 2000, Biochemistry.

[61]  P. Casey,et al.  Kinetic studies of protein farnesyltransferase mutants establish active substrate conformation. , 2003, Biochemistry.

[62]  C. Fierke,et al.  Mutagenesis Studies of Protein Farnesyltransferase Implicate Aspartate β352 as a Magnesium Ligand* , 2003, Journal of Biological Chemistry.

[63]  T. Nozaki,et al.  Molecular Cloning and Characterization of a Protein Farnesyltransferase from the Enteric Protozoan Parasite Entamoeba histolytica* , 2004, Journal of Biological Chemistry.

[64]  C. Fierke,et al.  Structural characterization of the zinc site in protein farnesyltransferase. , 2003, Journal of the American Chemical Society.

[65]  S. Sebti,et al.  Inhibitors of protein farnesyltransferase as novel anticancer agents. , 2002, Current Topics in Medicinal Chemistry.

[66]  P. Fernandes,et al.  Theoretical insights into the mechanism for thiol/disulfide exchange. , 2004, Chemistry.

[67]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[68]  P. Casey,et al.  High level expression of mammalian protein farnesyltransferase in a baculovirus system. The purified protein contains zinc. , 1993, The Journal of biological chemistry.

[69]  P. Casey,et al.  H-Ras peptide and protein substrates bind protein farnesyltransferase as an ionized thiolate. , 1998, Biochemistry.

[70]  A. W. Shaw,et al.  Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents. , 2003, Journal of medicinal chemistry.

[71]  P. Casey,et al.  Inhibition of purified p21 ras farnesyl:protein transferase by Cys-AAX tetrapeptides , 1990, Cell.

[72]  A. Ardizzoni,et al.  In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines. , 2004, Oncology reports.

[73]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[74]  S. Johnston,et al.  Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer. , 2001, The Lancet. Oncology.